Ocugen (OCGN) investor relations material

Executive summary

• Special Meeting scheduled for September 21, 2026, to vote on increasing authorized common stock by 250,000,000 shares and to approve adjournment if more votes are needed.

• Recent milestones include capital raising, debt repayment, a licensing partnership for OCU400, and progress on Phase 3 study design for OCU410.

• Plans for three BLA submissions by 2028, aiming to transition to a commercial-stage biotechnology company.

• Forward-looking statements highlight growth strategies, financing, partnerships, and regulatory progress, with risks detailed in recent SEC filings.

Voting matters and shareholder proposals

• Proposal 1: Amend charter to increase authorized common stock from 390,000,000 to 640,000,000 shares.

• Proposal 2: Approve adjournment of the meeting to solicit more proxies if Proposal 1 lacks sufficient votes.

• Board unanimously recommends voting FOR both proposals.

• Both proposals require a majority of voting power; abstentions count as votes against.

Board of directors and corporate governance

• Board and CEO actively communicate with shareholders and encourage written communications.

• Procedures for submitting director nominations and shareholder proposals for the 2027 Annual Meeting are outlined, with specific deadlines.